For people living with chronic obstructive pulmonary disease, clinical trials represent a meaningful path forward — connecting patients with cutting-edge treatments, expert medical teams, and research that shapes the future of lung care across the United States.
What COPD Clinical Trials Actually Involve
Clinical trials are structured research studies that evaluate how new medical approaches perform in real patients (source). For people managing COPD, these studies offer more than just access to experimental therapies — they provide an opportunity to receive attentive care from specialists who are deeply focused on advancing lung disease treatment. Participants contribute directly to a growing body of knowledge that benefits not only themselves but potentially millions of others living with the condition.
COPD trials typically involve a combination of tools to measure disease progression and treatment response. These can include breathing function tests, detailed imaging, biospecimen collection, and patient questionnaires (source). This multi-layered approach helps researchers build a more complete picture of how COPD develops and responds to intervention, particularly among people with a history of smoking.
Major Research Networks Driving COPD Studies
Several large-scale networks are actively organizing and running COPD clinical trials throughout the country. The American Lung Association’s Airways Clinical Research Centers (ACRC) Network holds the distinction of being the largest nonprofit network of clinical research centers in the nation dedicated to studying asthma and COPD treatments (source). Through this network, thousands of patients across multiple states have enrolled in ongoing research efforts.
Separately, the National Heart, Lung, and Blood Institute (NHLBI) funds the Pulmonary Trials Cooperative, which unites patients, researchers, and healthcare professionals from more than 50 institutions with the shared goal of developing new treatments for lung diseases, including several focused specifically on COPD (source). The breadth of institutions involved means that patients in many regions of the U.S. may have access to federally backed trial opportunities.
Patient Registries and the Power of Community Participation
Beyond individual trials, patient registries play a vital role in connecting researchers with people who are interested in participating in COPD studies. The COPD Patient-Powered Research Network, known as COPD PPRN, functions as a registry that has linked researchers with more than 75,000 patients who have expressed interest in contributing to COPD research (source). This large pool of engaged participants accelerates the pace at which new findings can be generated and validated.
The scale of participation matters enormously. Over 6,900 patients have already taken part in an ACRC clinical trial, and new studies continue to launch across the country (source). Each enrolled participant adds valuable data that researchers use to refine treatment approaches and identify which patient populations respond best to specific interventions.
Emerging Research Areas Shaping COPD Treatment
Some of the most compelling COPD research currently underway targets early disease detection and the role of airway mucus. The SPIROMICS SOURCE study, funded by the NHLBI, tracks individuals with a smoking history to detect the earliest measurable indicators of lung obstruction — before symptoms become severe (source). Identifying COPD at its earliest stages could dramatically change how and when treatment begins, potentially slowing disease progression for future patients.
Mucus blockages within medium and large airways have also emerged as a critical area of investigation. Research findings have linked heavier airway mucus obstruction to a higher risk of death in COPD patients, shifting scientific attention toward therapies designed to clear these blockages as a targeted treatment strategy (source). This represents a notable shift in how researchers conceptualize disease management beyond traditional bronchodilator therapies.
Geographic Disparities and the RURAL Study
COPD does not affect all communities equally. In rural areas of the American South, COPD rates are reported to be twice as high as those found in urban communities (source). Recognizing this imbalance, the NHLBI established the RURAL study in 2019 to examine how lifestyle choices, genetics, environmental exposures, and socioeconomic conditions contribute to the elevated rates seen in these regions (source).
By focusing research efforts on underserved populations, the RURAL study aims to close the knowledge gap around why certain communities bear a disproportionate burden of the disease. Findings from this study could eventually drive more equitable access to targeted COPD prevention and treatment programs in regions that have historically lacked both resources and research attention.
Why You Should Learn More About COPD Clinical Trials Today
COPD clinical trials represent one of the most dynamic frontiers in respiratory medicine, offering patients access to emerging therapies while simultaneously advancing scientific understanding of the disease. From early detection studies to targeted airway treatments and research addressing geographic health disparities, the landscape of COPD research is broad and actively evolving. Whether someone is recently diagnosed or has been managing COPD for years, exploring clinical trial opportunities through established networks like the ACRC or registries like the COPD PPRN can open doors to expert care and meaningful participation in the fight against lung disease. Staying informed about available studies is a practical step that could benefit both individual health outcomes and the broader patient community.